The estimated Net Worth of Alan B. Sandler is at least $1.17 Milion dollars as of 1 April 2022. Dr Sandler owns over 1,060 units of Zai Lab stock worth over $625,206 and over the last 4 years he sold ZLAB stock worth over $0. In addition, he makes $545,000 as Pres & Head of Global Devel. in Oncology at Zai Lab.
Dr has made over 1 trades of the Zai Lab stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 1,060 units of ZLAB stock worth $22,864 on 1 April 2022.
The largest trade he's ever made was exercising 1,060 units of Zai Lab stock on 1 April 2022 worth over $22,864. On average, Dr trades about 118 units every 0 days since 2021. As of 1 April 2022 he still owns at least 28,985 units of Zai Lab stock.
You can see the complete history of Dr Sandler stock trades at the bottom of the page.
Dr. Alan Bart Sandler M.D. is the Pres & Head of Global Devel. in Oncology at Zai Lab.
As the Pres & Head of Global Devel. in Oncology of Zai Lab, the total compensation of Dr D at Zai Lab is $545,000. There are 4 executives at Zai Lab getting paid more, with Dr. Ying Du having the highest compensation of $1,376,036.
Dr D is 64, he's been the Pres & Head of Global Devel. in Oncology of Zai Lab since . There are 5 older and 19 younger executives at Zai Lab. The oldest executive at Zai Lab Limited is John Diekman, 77, who is the Independent Director.
Alan's mailing address filed with the SEC is C/O ALX ONCOLOGY HOLDINGS INC., 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Zai Lab have traded over $44,173,112 worth of Zai Lab stock and bought 19,000 units worth $666,380 . The most active insiders traders include Ying Du, William Lis oraz John D Diekman. On average, Zai Lab executives and independent directors trade stock every 14 days with the average trade being worth of $432,845. The most recent stock trade was executed by Richard Gaynor on 3 September 2024, trading 2,500 units of ZLAB stock currently worth $48,750.
zai lab is a biopharmaceutical company dedicated to discovering, developing and commercializing innovative medicines. our vision is to address the largest unmet medical needs and transform patients’ lives around the world. we take a unique approach to combine both in-licensed products and internal r&d; to achieve a rich pipeline. we believe our drug candidates can be truly disease modifying and bring significant benefits to patients. the company was founded in 2013 by a group of industry veterans. the founders are known as pioneers in china’s fast advancing biotech industry with a proven track record for successful chinese cfda and us fda filings and approvals. our senior management team introduced fast regulatory approval pathways in china and developed a variety of partnership models with multinational pharmaceutical companies. we endeavor to conduct world class clinical development in china and beyond. zai lab has strong backing from a leading group of healthcare investors. our inve
Zai Lab executives and other stock owners filed with the SEC include: